Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference54 articles.
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD,
https://seer.cancer.gov/csr/1975_2015/
based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Accessed 8 June 2018.
3. Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, et al. Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34:3921–30.
4. Leleu X, Kyriakou C, Vande Broek I, Murphy P, Bacon P, Lewis P, et al. Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. Blood Cancer J. 2017;7:e543.
5. Mortensen GL, Salomo M. Quality of life in patients with multiple myeloma: a qualitative study. J Cancer Sci Ther. 2016;8:289–93.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献